Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
about
Pharmacogenetics and psychopharmacotherapy.Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population studyLimitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studiesThe activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel studyCYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosusPhenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians.Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolismDrug metabolism and genetic polymorphism in subjects with previous halothane hepatitis.Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations
P2860
Q33962212-0410AD83-A974-4A4A-9FD3-027F3114909EQ34345510-24E8163D-FEA6-4450-A4B3-EA1F6ABEB57FQ34346625-C05B0F85-0135-4800-ADF3-1B6A62AACC54Q34347507-0BDDD7C5-5076-4BC9-A5CE-9F5B6169C89EQ34358059-5A11A2B3-5A81-4E8B-9470-7C9F1E1D9989Q34358893-492E59D1-BF6E-4CFF-897C-BB6315119C93Q35548495-D6DDE235-4754-489E-B5D7-021F2F6125B6Q36053715-60824338-25DA-4379-B792-562D7D7DA77DQ38260323-174F7A2F-92DF-4D58-8858-EDA97EEC4E29Q38365410-6FD92DF2-11F8-428D-A0A9-4D23A0271F6FQ38616806-8BAAE00A-5801-4588-A1FF-0EE5A76DE868Q41931375-F7670898-8E5D-4299-BB44-6D41992D52CBQ42285032-114951AD-66E0-4A27-AFD9-D126AE6B9CBBQ42286097-0155E530-E9DC-49E1-95BB-CED785280878Q57382340-FC278560-1DA4-4CB7-8BB4-74CD2D3F0A51Q57586052-FE6E122D-7A84-4A76-AC74-1C123D2CD3D1
P2860
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
description
1989 nî lūn-bûn
@nan
1989 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
@ast
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
@en
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
@nl
type
label
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
@ast
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
@en
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
@nl
prefLabel
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
@ast
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
@en
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
@nl
P2093
P2860
P1476
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1989.TB03426.X
P407
P577
1989-05-01T00:00:00Z